BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sefaxersen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sefaxersen\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05797610-5037@assetmemo.bio
DTSTAMP:20261121T004101Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Sefaxersen: Phase 3 readout est. (NCT05797610)
DESCRIPTION:Sefaxersen\, phase 3\, IgA Nephropathy.\nStudy: A Study to Eval
 uate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants Wit
 h Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression\n
 Estimated primary completion: 25 May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sefaxersen#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05797610
URL:https://assetmemo.bio/drug/sefaxersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
